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Drugs: from prescription only to pharmacy only
The benefits are clearer than the risks
The range ofmedicines available over the pharmacy counter is
set to increase. I The Medicines Control Agency has revised its
procedures to speed up the reclassification from prescription
only medicine (POM) status to pharmacy only (P) status. In
addition, the Medicines Act has recently been revised to
ensure, by five yearly review, that the prescription only status
of a medicine continues to be justified.
Economic and philosophical considerations underlie these
moves. Economic considerations include an escalating growth
in spending on health care, which includes a drug bill,
growing at around 12% every year. One solution is to shift
more of the financial burden to individuals by encouraging
them to treat themselves with non-prescription drugs.
What is more, the current controls on drug spending have
constrained profits in the drug industry, so more companies
are moving into the over the counter market.2 The govern-
ment's philosophy on health care is that individuals should
take greater responsibility for their health3; trends towards
less medical paternalism and more consumerism favour
greater freedom to choose self treatment for palliation and
cure.
All drugs have some potential to cause harm, and reclassify-
ing some from prescription only to pharmacy only increases
the community's exposure to hazard: although the secretary
of state for health claimed that patients' safety would be a
prime consideration,' how good are the data on safety?
Clinical trials are usually done on a restricted range ofpatients
under controlled conditions and may not predict what
happens in general use. Postmarketing surveillance studies
are often poorly planned and executed,4 and the Committee
on Safety of Medicines collects only a small proportion of
adverse effects.
It can be difficult to extrapolate from similar changes in
other countries. For example, in Denmark cimetidine was
made available without prescription in 1989 and the pattern
of adverse reaction reports did not change.5 Changes in
reimbursement and advertising controls complicate inter-
pretations of the change in status, and the amount of the drug
sold over the counter was small, with much of it probably
bought by patients who had previously been prescribed it.
The true effect on the community will not be seen until the
drug is widely purchased by people who are taking drugs with
which cimetidine may have clinically serious interactions-
such as phenytoin, warfarin, and theophylline.
In Britain the Medicines Control Agency has the task
of assessing these data. Are the mechanisms to prevent
inappropriate use and detect adverse effects sufficiently
robust to support a substantial shift in policy? The main
checks to stop patients misusing a drug are restricting its sale
to a pharmacy (where the pharmacist need not speak to the
customer) and the inclusion of a readable patient information
leaflet. The effectiveness of a leaflet will depend not only on
the purchasers' ability to read and understand it but also on
whether they heed any warnings. Having spent their money,
customers may well choose to take the drug despite the leaflet.
How sensitive the yellow card system is for detecting serious
adverse effects of self medication is unclear. The risk of an
adverse effect depends on the drug, the population exposed to
it, and how it is used. Both the population and method of use
may change with a change of status.
New approaches to managing risk should accompany the
increase in drugs available without prescription. A strategy
based on gatekeeping, informing, and monitoring is needed.
In Australia pharmacists can fulfil these roles because of their
legal obligation to give advice and elicit information before
some drugs can be sold over the counter; while not perfect,
this approach has some merits. Perhaps all drugs that change
from prescription only to pharmacy status should be sold in
person by the pharmacist for the first three years. Information
would be given and elicited at each sale, depending on
whether the sale was for a first or repeat supply. Patients with
excessive use or suspected adverse effects would be referred to
their general practitioner. Gatekeeping could include the
pharmacist recommending only self medication from a list of
nationally agreed "preferred medicines."I
Overall, the shift from prescription only to pharmacy only
medicines should be welcomed as it gives greater freedom of
choice to patients and allows them to treat symptoms quickly.
But there are risks that patients may delay consulting about
serious conditions and that an unacceptably high incidence of
adverse effects may result from the way that the general
population uses the drug. In this risk-benefit equation only
the benefits are clear; the risks, and the burden of harm that
may accrue, are hard to predict. The push from prescription
only medicine to pharmacy only medicine needs to be
supported by further research, including anthropological
studies, and the new approaches to managing risk.
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